Shares of Inhibrx Biosciences INBX rallied 36.9% on Wednesday. The massive surge was triggered by encouraging updated interim ...

News and commentary from the world of gastroenterology and hepatology ...

Updated interim findings from a phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI demonstrate ...

Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...

A veteran diagnosed with stage 4 colon cancer was turned away by the Department of Veterans Affairs after being told he makes ...

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer ther ...

Six of eight patients (75%) with HER2-positive rectal adenocarcinoma responded to trastuzumab and tucatinib plus chemotherapy ...

While the incidence of colorectal cancer is decreasing among those over 50, it is rising at an alarming rate among younger ...

A new study reveals that malignant transformation of intestinal stem cells (ISCs) and their supportive microenvironment ...

After his colon cancer returned in full force, Marine Corps veteran Joe Worthy decided to help other veterans, advocating for ...